Under the multi-year relationship with Eli Lilly and Company, PrimeraDx will develop diagnostic products in support of multiple clinical development programs for novel therapeutics.
PrimeraDx president and CEO Matt McManus said, "These programs are a tremendous validation of our technology and its utility in the development of complex tests to better diagnose and treat patients."
Lilly clinical diagnostics laboratory senior director Andrew Schade said the ability of the ICEPlex System to combine multiple DNA and RNA biomarkers into a single multiplex assay could prove invaluable in the drive to develop companion diagnostics for crucial assets in the Lilly’s clinical pipeline.
"Our early focus will be in oncology, but as with all of our early research, we will apply learnings across therapeutic areas," Schade added.